Codi QR

Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2

Newly emerging SARS-CoV-2 variants may escape monoclonal antibodies (mAbs) and antiviral drugs. By using live virus assays, we assessed the ex vivo inhibition of the B.1 wild-type (WT), delta and omicron BA.1 and BA.2 lineages by post-infusion sera from 40 individuals treated with bamlanivimab/etese...

Descripció completa

Guardat en:
Autors principals: Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, Annalisa Bergna, Barbara Rossetti, Federica Giammarino, Camilla Biba, Anna Gidari, Alessia Lai, Cesira Nencioni, Daniela Francisci, Maurizio Zazzi, Ilaria Vicenti
Format: Artigo
Idioma:Inglês
Publicat: MDPI AG 2022-06-01
Col·lecció:Viruses
Matèries:
SARS-CoV-2
mAbs
nirmatrelvir
remdesivir
molnupiravir
microneutralization assay
Accés en línia:https://www.mdpi.com/1999-4915/14/7/1374
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars